MSB 7.69% $1.19 mesoblast limited

Ann: Day 180 Survival Outcomes In aGvHD Phase 3 Trial, page-68

  1. 12,393 Posts.
    lightbulb Created with Sketch. 3370
    I really like the sound of these quotes..
    " The FDA specifically wanted this study done to ensure it was a clean study where these children had not been offered or taken any other drugs ,so it's first line therapy "
    " The results are a milestone not only for Mesoblast but for regenerative medicine , we are a long way ahead of any competition "
    ...
    We are going to get an avalanche of news - stay tuned
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.